125285 -

July 7, 2017 Approval Letter - BLA 125285/290 Flublok and ... - FDA

At first glance, it’s just a number. In reality, it represents the FDA's authorization of Flublok Quadrivalent, a breakthrough in how we manufacture vaccines. What Makes 125285 Special?

Here is a blog post exploring why this specific number matters in the fight against the flu. 125285

: Flublok Quadrivalent contains three times the active ingredient (antigen) of standard-dose flu vaccines, which is designed to provide a stronger immune response.

Clinical reviews associated with STN 125285 show that the vaccine is effective in preventing laboratory-confirmed influenza. Like any vaccine, it can have side effects—most commonly pain at the injection site, headache, or fatigue—but these are typically mild and short-lived. The Bottom Line July 7, 2017 Approval Letter - BLA 125285/290 Flublok and

While "125285" might look like a random string of numbers, it is actually a significant identifier in the world of public health and pharmaceutical regulation. Most notably, is the Biologics License Application (BLA) Submission Tracking Number (STN) assigned by the FDA for Flublok , a unique type of influenza vaccine.

According to FDA-approved labeling , Flublok is indicated for active immunization against influenza A and B in adults . It is often recommended for older adults who may need that extra "boost" in protection, though it is widely available for the general adult population. Safety and Efficacy What Makes 125285 Special

Most traditional flu vaccines are grown in chicken eggs—a process that has remained largely unchanged for decades. However, the product filed under BLA STN 125285 is different. Manufactured by Protein Sciences Corporation (a Sanofi company), Flublok is a . Here is what that means for you: